09 and 10 September 2020
During an inspection looking at part of the service
This report was created as part of a pilot which looked at new and innovative ways of fulfilling CQC’s regulatory obligations and responding to risk in light of the Covid-19 pandemic. This was conducted with the consent of the provider. Unless the report says otherwise, we obtained the information in it without visiting the Provider.
We previously carried out an announced comprehensive inspection at Meir Park Surgery on 6 March 2019 as part of our inspection programme. The practice was rated inadequate, placed into special measures and a warning notice in relation to safe care and treatment was issued. We carried out an announced focused inspection at Meir Park Surgery on 30 April 2019 and found that the issues identified in the warning notice had been partially addressed. A follow up comprehensive inspection was carried out on 16 September 2019. We found there had been some improvement. The practice was taken out of special measures and rated requires improvement overall. In response to issues shared with the CQC, we carried out an unrated, focused inspection on 26 May 2020 where concerns were found in relation to safe care and treatment of patients and governance. Conditions were imposed on the practice’s registration with the CQC. The full reports on the inspections carried out in March, April and September 2019 and May 2020 can be found by selecting the ‘all reports’ link for Meir Park Surgery on our website at www.cqc.org.uk.
We carried out an announced pilot inspection at Meir Park Surgery on 9 and 10 September 2020.
We based our judgement of the quality of care at this service on a combination of:
- what we found when we inspected.
- information from our ongoing monitoring of data about services.
- information from the provider and other organisations.
We found that:
- An overall, prescribing clinical lead had been appointed to provide clinical oversight of the management of medicines.
- Policies and procedures had been developed to support appropriate management of medicines. However, policies were not always adhered to and systems to deal with behaviour inconsistent with the policies were under review.
- Systems to ensure clinical oversight of hospital letters informing changes to patients’ care and treatment had been put in place. However, the pace of review was slow and below the practice’s own target rate of completion.
- There had been some improvement in the monitoring of patients prescribed high-risk medicines. However, policies for the monitoring of patients prescribed warfarin were not in place and guidance in Medicines and Healthcare products Regulatory Agency alerts was not always adhered to.
- Patients were prescribed high numbers of controlled drugs with a lack of clinical review.
- The practice culture did not effectively support high quality sustainable care.
- To support governance arrangements, there had been positive changes in the management structure.
- Poor medicine oversight, response to correspondence from hospitals and ineffective systems for the coding of health conditions and treatment within patients’ records demonstrated systemic governance issues and a failure to fully embed new changes into practice.
We were significantly concerned about the proposed timescale for completion of the review of hospital letters and that the safety of patients continued to be a risk. We have informed the practice that they must increase the pace of this work and complete it within one month. We will continue to monitor their progress closely and discuss with external partners with a view to deciding what further action, if any, we might take.
Details of our findings and the supporting evidence are set out in the evidence table.
Dr Rosie Benneyworth BS BM BMedSci MRCGP
Chief Inspector of Primary Medical Services and Integrated